In a report released today, Debjit Chattopadhyay from H.C. Wainwright initiated coverage with a Buy rating on Autolus Therapeutics Plc (NASDAQ: AUTL) and a price target of $45. The company’s shares closed yesterday at $30.64.
According to TipRanks.com, Chattopadhyay has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.0% and a 36.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Autolus Therapeutics Plc has an analyst consensus of Moderate Buy, with a price target consensus of $45.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.22 and a one-year low of $19.17. Currently, Autolus Therapeutics Plc has an average volume of 50.05K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc operates as a holding company, which engages in the development of cancer treatments. Its portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
